The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Uncovering the distinct dynamics of response to teclistamab treatment in HR-SMM versus R/R myeloma
Nayda Bidikian, MD, Dana-Farber Cancer Institute, Boston, MA, provides insight into the longitudinal single-cell immune profiling of patients with high-risk smoldering multiple myeloma (HR-SMM) or relapsed/refractory (R/R) multiple myeloma (MM) receiving teclistamab. Dr Bidikian discusses the significant differences in the immune composition of the peripheral blood observed at baseline between the groups and then highlights the distinct dynamics of response to teclistamab. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
